NKTR insider transaction filings

NEKTAR THERAPEUTICS — 36 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-08-20. Screen NKTR transaction legs live →

FiledFormInsiderReported transactionsSource
2026-08-204Zalevsky Jonathan — Chief R&D OfficerSale (S): 186 @ $71.98EDGAR
2026-08-204ROBIN HOWARD W — President & CEO, DirectorSale (S): 418 @ $71.98EDGAR
2026-07-244ROBIN HOWARD W — President & CEO, DirectorGrant/award (A): 57,200 (derivative) @ $0EDGAR
2026-07-244Zalevsky Jonathan — Chief R&D OfficerGrant/award (A): 16,500 (derivative) @ $0EDGAR
2026-07-024Zalevsky Jonathan — Chief R&D OfficerSale (S): 5,681 @ $70EDGAR
2026-06-184ROBIN HOWARD W — President & CEO, DirectorSale (S): 5,303 @ $59.97 · Sale (S): 4,697 @ $60.71 · Sale (S): 5,500 @ $60.81 · Sale (S): 4,500 @ $61.65EDGAR
2026-06-174Zalevsky Jonathan — Chief R&D OfficerSale (S): 5,538 @ $60.71EDGAR
2026-05-214Zalevsky Jonathan — Chief R&D OfficerSale (S): 199 @ $65.51EDGAR
2026-05-214ROBIN HOWARD W — President & CEO, DirectorSale (S): 444 @ $65.51EDGAR
2026-02-204Zalevsky Jonathan — Chief R&D OfficerSale (S): 180 @ $73EDGAR
2026-02-204ROBIN HOWARD W — President & CEO, DirectorSale (S): 423 @ $73EDGAR
2026-01-224Zalevsky Jonathan — Chief R&D OfficerSale (S): 3,867 @ $35.67EDGAR
2025-12-234Zalevsky Jonathan — Chief R&D OfficerGrant/award (A): 6,250 @ $0 · Grant/award (A): 25,000 (derivative) @ $0EDGAR
2025-12-234ROBIN HOWARD W — President & CEO, DirectorGrant/award (A): 21,667 @ $0 · Grant/award (A): 86,667 (derivative) @ $0EDGAR
2025-11-254Wilson Mark Andrew — Chief Legal OfficerGrant/award (A): 1,903 @ $0 · Sale (S): 630 @ $54.28 · Grant/award (A): 3,400 (derivative) @ $0EDGAR
2025-11-254Zalevsky Jonathan — Chief R&D OfficerGrant/award (A): 2,666 @ $0 · Sale (S): 1,157 @ $54.28 · Grant/award (A): 4,766 (derivative) @ $0EDGAR
2025-11-254ROBIN HOWARD W — President & CEO, DirectorGrant/award (A): 7,110 @ $0 · Sale (S): 2,207 @ $54.28 · Grant/award (A): 12,170 (derivative) @ $0EDGAR
2025-10-014WHITFIELD ROY A — DirectorGrant/award (A): 8,000 (derivative) @ $0EDGAR
2025-10-014Brainard Diana — DirectorGrant/award (A): 8,000 (derivative) @ $0EDGAR
2025-10-014Ajer Jeffrey Robert — DirectorGrant/award (A): 8,000 (derivative) @ $0EDGAR
2025-10-014CHESS ROBERT — DirectorGrant/award (A): 8,000 (derivative) @ $0EDGAR
2025-10-014GREER R SCOTT — DirectorGrant/award (A): 8,000 (derivative) @ $0EDGAR
2025-09-114ROBIN HOWARD W — President & CEO, DirectorSale (S): 2,100 @ $45.16 · Sale (S): 1,200 @ $46.41 · Sale (S): 2,156 @ $47.49 · Sale (S): 1,210 @ $48.18EDGAR
2025-09-084Zalevsky Jonathan — Chief R&D OfficerSale (S): 793 @ $32.43 · Sale (S): 432 @ $33.60 · Sale (S): 189 @ $34.41 · Sale (S): 307 @ $35.69EDGAR
2025-09-084ROBIN HOWARD W — President & CEO, DirectorSale (S): 1,923 @ $32.37 · Sale (S): 1,496 @ $33.54 · Sale (S): 613 @ $34.40 · Sale (S): 1,134 @ $35.80 · Sale (S): 3,304 @ $37.87 · Sale (S): 2,226 @ $38.82 · +1 moreEDGAR
2025-09-044Zalevsky Jonathan — Chief R&D OfficerSale (S): 485 @ $30.10EDGAR
2025-09-044ROBIN HOWARD W — President & CEO, DirectorSale (S): 1,500 @ $30.16EDGAR
2025-08-214Wilson Mark Andrew — Chief Legal OfficerSale (S): 676 @ $26.59 · Grant/award (A): 21,666 (derivative) @ $0EDGAR
2025-08-214Zalevsky Jonathan — Chief R&D OfficerSale (S): 725 @ $26.59 · Grant/award (A): 16,666 (derivative) @ $0EDGAR
2025-08-214ROBIN HOWARD W — President & CEO, DirectorSale (S): 1,573 @ $26.59 · Grant/award (A): 86,666 (derivative) @ $0EDGAR
2025-05-214Wilson Mark Andrew — Chief Legal OfficerSale (S): 9,996 @ $0.67EDGAR
2025-05-214Zalevsky Jonathan — Chief R&D OfficerSale (S): 10,712 @ $0.67EDGAR
2025-05-214ROBIN HOWARD W — President & CEO, DirectorSale (S): 23,208 @ $0.67EDGAR
2025-02-214Wilson Mark Andrew — Chief Legal OfficerSale (S): 11,040 @ $1.01EDGAR
2025-02-214Zalevsky Jonathan — Chief R&D OfficerSale (S): 10,300 @ $1.01EDGAR
2025-02-214ROBIN HOWARD W — President & CEO, DirectorSale (S): 23,774 @ $1.01EDGAR

Recent 8-K events — NEKTAR THERAPEUTICS

FiledFormItems reportedSource
2026-08-138-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2026-06-058-K5.07 — Submission of Matters to a Vote of Security HoldersEDGAR
2026-05-088-K1.01 — Entry into a Material Definitive Agreement
5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
9.01 — Financial Statements and Exhibits
EDGAR
2026-05-078-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2026-04-238-K1.01 — Entry into a Material Definitive Agreement
8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2026-04-208-K7.01 — Regulation FD DisclosureEDGAR
2026-04-208-K7.01 — Regulation FD Disclosure
8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2026-03-128-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2026-02-138-K1.01 — Entry into a Material Definitive Agreement
8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2026-02-108-K7.01 — Regulation FD DisclosureEDGAR
Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?ticker=NKTR returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →